187 related articles for article (PubMed ID: 19643773)
1. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
Di Biagio A; Rosso R; Siccardi M; D'Avolio A; Bonora S; Viscoli C
J Antimicrob Chemother; 2009 Oct; 64(4):874-5. PubMed ID: 19643773
[No Abstract] [Full Text] [Related]
2. Successful tacrolimus treatment following renal transplant in a HIV-infected patient with raltegravir previously treated with a protease inhibitor based regimen.
Cousins D; Topping K; Lee V; Sweeney J; Lawton M
Drug Metabol Drug Interact; 2011; 26(3):139-41. PubMed ID: 21980965
[TBL] [Abstract][Full Text] [Related]
3. FDA notifications. FDA grants approval for raltegravir.
AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
[No Abstract] [Full Text] [Related]
4. Effects of omeprazole on plasma levels of raltegravir.
Iwamoto M; Wenning LA; Nguyen BY; Teppler H; Moreau AR; Rhodes RR; Hanley WD; Jin B; Harvey CM; Breidinger SA; Azrolan N; Farmer HF; Isaacs RD; Chodakewitz JA; Stone JA; Wagner JA
Clin Infect Dis; 2009 Feb; 48(4):489-92. PubMed ID: 19143531
[TBL] [Abstract][Full Text] [Related]
5. [Raltegravir as first integrase inhibitor in an HIV-infection].
Papendorp SG; Brinkman K
Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
[No Abstract] [Full Text] [Related]
6. [CROI 2012: updates on raltegravir].
MMW Fortschr Med; 2012 May; 154 Suppl 1():41. PubMed ID: 22916600
[No Abstract] [Full Text] [Related]
7. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs.
Tricot L; Teicher E; Peytavin G; Zucman D; Conti F; Calmus Y; Barrou B; Duvivier C; Fontaine C; Welker Y; Billy C; de Truchis P; Delahousse M; Vittecoq D; Salmon-Céron D
Am J Transplant; 2009 Aug; 9(8):1946-52. PubMed ID: 19519819
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir can be used safely in HIV-1-infected patients treated with warfarin.
Honda H; Gatanaga H; Aoki T; Watanabe K; Yazaki H; Tanuma J; Tsukada K; Honda M; Teruya K; Kikuchi Y; Oka S
Int J STD AIDS; 2012 Dec; 23(12):903-4. PubMed ID: 23258834
[TBL] [Abstract][Full Text] [Related]
10. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation.
Moreno A; Bárcena R; Quereda C; Casado JL; Pérez-Elías MJ; Fortún J; Nuño J; Arranz I; Moreno S
AIDS; 2008 Feb; 22(4):547-8. PubMed ID: 18301075
[No Abstract] [Full Text] [Related]
11. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
[No Abstract] [Full Text] [Related]
12. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.
Bickel M; Anadol E; Vogel M; Hofmann WP; von Hentig N; Kuetscher J; Kurowski M; Moench C; Lennemann T; Lutz T; Bechstein WO; Brodt HR; Rockstroh J
J Antimicrob Chemother; 2010 May; 65(5):999-1004. PubMed ID: 20202988
[TBL] [Abstract][Full Text] [Related]
13. A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.
Turkova A; Ball C; Gilmour-White S; Rela M; Mieli-Vergani G
J Antimicrob Chemother; 2009 Mar; 63(3):623-5. PubMed ID: 19164417
[No Abstract] [Full Text] [Related]
14. Clinical management of the HIV-positive kidney transplant recipient.
Carlson L
Nephrol Nurs J; 2008; 35(6):559-67; quiz 568. PubMed ID: 19260607
[TBL] [Abstract][Full Text] [Related]
15. Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?
Cattaneo D; Puoti M; Sollima S; Moioli C; Foppa CU; Baldelli S; Clementi E; Gervasoni C
J Antimicrob Chemother; 2016 May; 71(5):1341-5. PubMed ID: 26755497
[TBL] [Abstract][Full Text] [Related]
16. No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.
Singh GJ; Jackson A; D'Avolio A; Else L; De Nicolò A; Bonora S; Di Perri G; Khoo S; Back D; Moyle G; Boffito M
AIDS; 2014 Aug; 28(13):1993-5. PubMed ID: 25259708
[No Abstract] [Full Text] [Related]
17. Impact of cyclosporine-based immunosuppressive therapy on liver histology of hepatitis C virus-infected renal transplant patients.
Schiavon LL; Carvalho-Filho RJ; Narciso-Schiavon JL; Barbosa DV; Lanzoni VP; Ferraz ML; Silva AE
Hepatology; 2008 Jul; 48(1):348-9. PubMed ID: 18521870
[No Abstract] [Full Text] [Related]
18. Raltegravir treatment response in an HIV-2 infected patient: a case report.
Garrett N; Xu L; Smit E; Ferns B; El-Gadi S; Anderson J
AIDS; 2008 May; 22(9):1091-2. PubMed ID: 18520356
[No Abstract] [Full Text] [Related]
19. Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.
Fleischbein E; O'Brien J; Martelino R; Fenstersheib M
AIDS; 2008 Nov; 22(17):2404-5. PubMed ID: 18981785
[No Abstract] [Full Text] [Related]
20. [Integrase inhibition].
Bogner JR
MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
